Table 1.
Primary maternal and foetal outcomes
| Anticoagulation regimen | Maternal mortality |
Thromboembolism |
Livebirth rate |
Anticoagulant-related foetal/ | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| neonatal adverse events | ||||||||||||||||
| Studies | Events | Estimate (%) | I2 (%) | Studies | Events | Estimate (%) | I2 (%) | Studies | Events | Estimate (%) | I2 (%) | Studies | Events | Estimate (%) | I2 (%) | |
| Vitamin K antagonists (INR target 2.5-3.5) | 11 | 7/581 | 0.9 (0.1, 1.6) | 0 | 11 | 22/581 | 2.7 (1.4, 4.0) | 0 | 10 | 369/531 | 64.5 (48.8, 80.2) | 95 | 11 | 12/407 | 2.0 (0.3, 3.7)a | 24 |
| Sequential treatment | 20 | 11/530 | 2.0 (0.8, 3.1) | 0 | 20 | 44/530 | 5.8 (3.8, 7.7) | 29 | 18 | 381/475 | 79.9 (74.3, 85.6) | 61 | 19 | 5/431 | 1.4 (0.3, 2.5)b | 0 |
| LMWH alone | 10 | 1/132 | 2.9 (0.2, 5.7) | 0 | 9 | 13/127 | 8.7 (3.9, 13.4) | 0 | 7 | 68/74 | 92.0 (86.1, 98.0) | 0 | 8 | 0/103 | NA | 0 |
| UFH alone | 4 | 2/64 | 3.4 (0, 7.7) | 0 | 3 | 7/52 | 11.2 (2.8, 19.6) | 0 | 3 | 33/51 | 69.5 (37.8, 100) | 87 | 4 | 4/44 | 7.6 (0.1, 15.0)b | 0 |
INR, international normalized ratio; LMWH, low molecular weight heparin; NA, not applicable; UFH, unfractionated heparin.
Estimates are presented as proportions per 100 affected pregnancies with 95% confidence intervals.
a
Of these 7/407 [0.8% (0.0, 1.7)] represent embryopathy and 5/197 [2.1% (0.1, 4.1)] represent foetopathy.
b
All cases represent foetopathy.